-
2022-500311-39-00
6
2022-09-08
Patients with Crohn's disease undergoing surgery and having at least o
-
2022-502373-42-00
5
2022-04-25
Oligorecurrent hormone-sensitive prostate cancer patients
-
2023-505438-85-00
5
2022-01-12
Acute myocardial infarction (AMI)
-
2023-506857-40-00
5
2019-01-08
Prostate Cancer
-
2025-521067-13-00
5
2026-04-24
Atherosclerotic Cardiovascular Disease (ASCVD)
-
2024-512925-95-00
5
2025-05-16
Advanced/Metastatic Breast Cancer
-
2024-518343-38-00
5
2025-02-12
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2024-511016-25-00
4
2025-01-15
Chronic hepatitis B infection
-
2024-513015-27-00
5
2025-01-09
Moderately to Severely Active Ulcerative Colitis (UC)
-
2023-510487-12-00
4
2024-11-29
Crohn's Disease
-
2023-505989-29-00
5
2024-11-21
Extensive stage small cell lung cancer (ES-SCLC)
-
2023-505617-24-00
4
2024-11-05
Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression
-
2024-510581-17-00
4
2024-11-05
Adult subjects with New York Heart Association (NYHA) Class III conges
-
2024-510908-37-00
5
2024-08-28
KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (
-
2024-512023-37-00
4
2024-06-27
Prostate cancer
-
2022-502954-15-00
4
2024-06-21
Idiopathic pulmonary fibrosis
-
2023-506457-38-00
5
2024-06-05
Chronic kidney disease (CKD) and hypertension.
-
2023-508630-34-00
5
2024-05-28
Overweight
-
2023-508166-15-00
6
2024-04-29
Ulcerative colitis (UC), Inflammatory bowel disease type unclassified
-
2023-504471-25-00
5
2024-03-01
Fibrotic Lung Disease
-
2023-503265-27-00
5
2023-11-23
Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Co
-
2022-502779-40-00
5
2023-09-04
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2022-501419-15-00
5
2023-08-23
Atrial Fibrillation
-
2022-501352-28-00
5
2023-06-07
Severe community-acquired pneumonia (sCAP)